forum

CIPLA Share Price Discussion

Cipla Ltd.
Sector: Pharmaceuticals and health care
... Read more
CIPLA Share Price *
470 +1 (0.21%)
* (quote may be delayed)

CIPLA Discussion Forum


INTRA DAY BUY CIPLA ON NSE @ 470-71, SL 469, TGT 475, 482
Like
reply
Reply
share
Share
santosh gupta in CIPLA
Santosh Gupta: SELL CIPLA BELOW 468.50

ONCE EXIT SHORT IN CIPLA AT 469. BOOK LOSS RS. 500.00. NSE
Like
reply
Reply
share
Share

**OPTION CALL**
================
**STOCK:** CIPLA 460 PE @ 5.70
**STOPLOSS :** YOURS
**TARGET: ** 7.00
**LOT SIZE:** 1000
Like
reply
Reply (3)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Sep 13 5:09 PM

5.95
INTRADAY Options @teamIOFno
Sep 13 5:10 PM

6.00
INTRADAY Options @teamIOFno
Sep 13 6:04 PM

6.30

Santosh Gupta:
SELL CIPLA BELOW 468.50
Like
reply
Reply
share
Share

**OPTION CALL**
================
**STOCK:** ASIANPAINT 1560 CE @ 20.65
**STOPLOSS :** YOURS
**TARGET: ** 24.00
**LOT SIZE:** 600
Like
reply
Reply
share
Share

**OPTION CALL**
================
**STOCK:** CIPLA 480 CE @ 5.45
**STOPLOSS :** YOURS
**TARGET: ** 7.00
**LOT SIZE:** 1000
Like
reply
Reply (4)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Sep 12 5:54 PM

6.05
INTRADAY Options @teamIOFno
Sep 12 6:08 PM

6.30
INTRADAY Options @teamIOFno
Sep 12 6:13 PM

6.45
INTRADAY Options @teamIOFno
Sep 12 7:02 PM

7.00

Santosh Gupta:
FOM: ONCE EXIT SHORT IN CIPLA AT 468.50. BOOK PROFIT RS. 4,500.00. NSE
Like
reply
Reply
share
Share
robotrade in CIPLA
Cipla fut buy@ 474 sl 469 Tgt 482/488✋

Sl rev 466
Like
reply
Reply
share
Share
robotrade in CIPLA
High probability trade

Buy 474
Like
reply
Reply
share
Share

Cipla buy 477
Sl 474 tgt 480,483
Like
reply
Reply
share
Share
robotrade in CIPLA
Cipla fut buy@ 474 sl 469 Tgt 482/488✋

High probability trade
Like
reply
Reply
share
Share

Cipla fut buy@ 474 sl 469
Tgt 482/488✋
Like
reply
Reply
share
Share
Top 10 high-conviction buying ideas from brokerage firms in a volatile market
Corporate banks, insurance, healthcare services, oil and gas, construction, engineering and logistics are among the key overweight sectors.
Moneycontrol
Like
reply
Reply
share
Share

**OPTION CALL**
**********************
**STOCK**: CIPLA 480 CE 12.60
**STOP LOSS:** YOURS
**TARGET:** 14.00
**LOT SIZE:** 1000
Like
reply
Reply (5)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Sep 6 6:14 PM

13.00
INTRADAY Options @teamIOFno
Sep 6 6:16 PM

13.30
INTRADAY Options @teamIOFno
Sep 6 6:22 PM

13.50
INTRADAY Options @teamIOFno
Sep 6 6:25 PM

13.60
INTRADAY Options @teamIOFno
Sep 6 6:25 PM

13.90

Buy Cipla 480 CE at 12.4
Target 18-24+
Sl below 10.2
Like
reply
Reply (1)
share
Share
Latest replies

Cipla 13.80 !!
robotech trade in CIPLA
Buy cipla 472 sl 467

479 cipla
Like
reply
Reply
share
Share

Buy Cipla 480 CE at 11.70
Target 18+
Sl below 9.6
Like
reply
Reply (1)
share
Share
Latest replies

12.70 !!

Buy cipla 472 sl 467
Like
reply
Reply
share
Share

CIPLA - 339063
buy cipla above 466.7 target 472.5-478-483 stoploss 464.95
Like
reply
Reply
share
Share

CIPLA...472
BUY RANGE...CMP TO 458
PUT 455 AS CBSL
EXPECT TARGET 485/499+
Like
reply
Reply
share
Share

Cipla sell @ 465.25
Sl 468
Tgt 462,460
1
reply
Reply (3)
share
Share
Latest replies

CIPLA MADE LOW OF 462.65❤️❤️

Target hit 🎯🎯🎯🎯🎯... Hope u all like my calls

Cipla 460 🔥🔥❤️✌️✌️✌️ 2nd target hit 🎯🎯🎯
robotech trade in CIPLA
Active 463

👉😁😆😂472
Like
reply
Reply
share
Share
Explainer: How Indian pharma companies are riding the biosimilars wave
A Morgan Stanley report says that as many as nine biologic drugs have either gone off patent or will do so by 2025, with combined revenues of $62 billion in 2018.
Moneycontrol
Like
reply
Reply
share
Share
Nearly 30 stocks saw FY20 EPS downgrades in last 4 qtrs; time to exit?
Most brokerage firms have downgraded EPS estimates for Nifty. There are as many as 28 stocks in BSE100 that saw FY20 EPS downgrades in the last four quarters
Moneycontrol
Like
reply
Reply
share
Share
robotech trade in CIPLA
Cipla buy @463/464 sl 456💎

Active 463
Like
reply
Reply
share
Share

CIPLA - chart - 328026

Like
reply
Reply
share
Share

Cipla buy @463/464 sl 456💎
Like
reply
Reply
share
Share
Cipla shares fall 2% after Credit Suisse cuts target price
Credit Suisse cut FY20/FY21 EPS estimates by 10/14 percent and factored in lower US sales & profits in estimates.
Moneycontrol
Like
reply
Reply
share
Share
'Another 5-8% correction still overdue, but HUL, Kotak Bank, HDFC, Nestle can reach new highs'
It should be on priority to add stocks which are beaten down with blue-chip status, visible earnings, good track record and future growth and of course clean books to be added at the present level, Mustafa Nadeem says
Moneycontrol
Like
reply
Reply
share
Share
Q. Bought at 510

Wait or exit? please comment
Like
reply
Reply (3)
share
Share
Latest replies
Dhruv @DhruvMan
Aug 24 9:43 PM

What is your position? I'd say you can wait for some recovery. Till about 485 levels. Its fairly over sold.
Raja @raja-SJtykD8mS
Aug 24 10:21 PM

300 quantity

Friend, you must have a time period Set for your target Profit. So please stick with it...Otherwise Trade with Equity other than Investment...You should have average out some when the Price went to as low as 450!!
Now the loss is big ..so wait it out...This is my earnest request ...
Watch out! Top 10 stocks brokerages downgraded post June quarter
Of 114 companies it covers, 36 percent of companies' earnings were below expectations, 15 percent were in-line and 49 percent were above estimates, CLSA said.
Moneycontrol
Like
reply
Reply
share
Share
Market consolidates amid hopes of govt intervention; more than 470 stocks hit 52-week low, rupee falls to 72/$
The Indian rupee fell to 72.04 against the US dollar, the lowest level since November 14, 2018, due to stronger dollar and FII outflow.
Moneycontrol
Like
reply
Reply
share
Share

Sell Cipla @ 476.2
Sl 479 TGT 473,470
1
reply
Reply (3)
share
Share
Latest replies

Cipla 50 points points⏬

Exit at minor gain market turning positive

The call what I given in the morning.... It was absolutely profitable trade.... 5 points down as now..
CIPLA short call suggested at 476..
Now made low of 471 🎯🎯🎯
rajiv kumar jha in CIPLA
Cipla buy fut@472/73 sl 467

480🍁😁
Like
reply
Reply
share
Share

Cipla buy fut@472/73 sl 467
Like
reply
Reply
share
Share

"RISKY JACKPOT"
CIPLA SELL BELOW 476
SL 477
TARGET "OPEN"
Like
reply
Reply (2)
share
Share
Latest replies

NEW LOW 472🔥
(-1000/- RISK PER LOT)😍
RISK 1: 4 TIMES PROFIT❤️
4,000/- PROFIT TILL NOW👍

NEW LOW 471.10🔥
(-1000/- RISK PER LOT)😍
RISK 1: 5 TIMES PROFIT❤️
4,900/- PROFIT TILL NOW👍
rajiv kumar jha in CIPLA
Ciplabuy@473/474 sl 469 Tgt open👆q-200/300

Not activate
Like
reply
Reply
share
Share

Ciplabuy@473/474 sl 469
Tgt open👆q-200/300
Like
reply
Reply
share
Share

Cipla fut buy 478
Sl-470 hold🔥🔥4/6 days trg-483/485/490++
Like
reply
Reply (1)
share
Share
Latest replies
Rajmudra Stock @rajmudra
Aug 19 3:59 PM

Second target achieve 485.60
Total profit 4600+/ per lot 🥰🥰😘😘

Sell CIPLA CASH 478 SL 481 TGT 474, 470
Like
reply
Reply
share
Share

Buy cipla 481 sl 474
Like
reply
Reply
share
Share

Intraday Bought #cipla @ 478.5-479 sl 0.5% #TurtleStrategy
Like
reply
Reply (1)
share
Share
Latest replies

Intraday Bought cipla @ 478.5-479 sl 0.5%...............slhit
Arrowmoney in CIPLA
Nifty Pharma Index What we have Posted.... - Cipla -1.67% 🔻 - Divis Lab -8.75% 🔴🔴🔴

Nifty Pharma Index
Today Extended Fall in Gap-up Open market
- Cipla -1.48% 🔻
- AuroPharma -3.02% 🔴
- Divis Lab -3.57% 🔴
Like
reply
Reply
share
Share
Money Market Operations as on February 20, 2014
Money Market Operations as on February 20, 2014
moneycontrol.com
Like
reply
Reply
share
Share
Arrowmoney in CIPLA
CIPLA Broken 500 🔻 Ready for 485-478-464-434 🔻

CIPLA
Made Low 475
T2=478 Achieved 🏆🏆
Like
reply
Reply
share
Share
Arrowmoney in CIPLA
Nifty Pharma Index Forming Bearish Head & shoulder Pattern Expecting after tomorrow Gap-up Openi...

Nifty Pharma Index
What we have Posted....
- Cipla -1.67% 🔻
- Divis Lab -8.75% 🔴🔴🔴
Like
reply
Reply
share
Share

CIPLA - chart - 309034
Nifty Pharma Index
Forming Bearish Head & shoulder Pattern
Expecting after tomorrow Gap-up Opening
but, market will remember that Fin Minister still has no comment on FPI tax
and again correction of last rally may start 🔻
next Correction may lead by Pharma Stocks
- Cipla
- Auro...
Read more...
1
reply
Reply
share
Share
Buy Cipla; target of Rs 650: Sharekhan
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 650 in its research report dated August 07, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Hold Cipla; target of Rs 520: ICICI Direct
ICICI Direct recommended hold rating on Cipla with a target price of Rs 520 in its research report dated August 09, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Arrowmoney in CIPLA
CIPLA Sharp fall from 499 to 493 ⤵️

*CIPLA*
Finally Achieved T1=485 🏆
Next TGT 478-464
Like
reply
Reply
share
Share
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA Share Price - Technicals

    keyboard_arrow_down
    CIPLA - 52 Week High₹678.45
    CIPLA - 52 Week Low₹449.2
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    13-Aug-19SharekhanBuy650
    9-Aug-19ICICIdirect.comHold520
    8-Aug-19Prabhudas LilladherReduce439
    8-Aug-19Nirmal BangBuy636
    24-May-19Nirmal BangBuy653
    View all CIPLA - Share Targets - Broker Reports
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 16467472464.1470.5
    Sep 13468.05469.65464.5469
    Sep 12474474464.4467.8
    Sep 11474478.3468.05471.8
    Sep 9475478.7472.1475
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹470.54
    30 Day Moving Average₹481.31
    50 Day Moving Average₹505.41
    100 Day Moving Average₹531.71
    200 Day Moving Average₹529.43
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 9 9:38 PM
    Top 10 high-conviction buying ideas from brokerage firms in a volatile market
    Moneycontrol
    NewsBot
    Aug 28 2:08 AM
    Explainer: How Indian pharma companies are riding the biosimilars wave
    Moneycontrol
    NewsBot
    Aug 27 3:38 PM
    Nearly 30 stocks saw FY20 EPS downgrades in last 4 qtrs; time to exit?
    Moneycontrol
    NewsBot
    Aug 26 5:48 PM
    Cipla shares fall 2% after Credit Suisse cuts target price
    Moneycontrol
    NewsBot
    Aug 25 6:13 PM
    'Another 5-8% correction still overdue, but HUL, Kotak Bank, HDFC, Nestle can reach new highs'
    Moneycontrol
    NewsBot
    Aug 23 7:08 PM
    Watch out! Top 10 stocks brokerages downgraded post June quarter
    Moneycontrol
    NewsBot
    Aug 23 5:38 PM
    Market consolidates amid hopes of govt intervention; more than 470 stocks hit 52-week low, rupee falls to 72/$
    Moneycontrol
    NewsBot
    Aug 14 12:03 AM
    Money Market Operations as on February 20, 2014
    moneycontrol.com
    NewsBot
    Aug 12 10:38 PM
    Buy Cipla; target of Rs 650: Sharekhan
    moneycontrol.com
    NewsBot
    Aug 12 9:38 PM
    Hold Cipla; target of Rs 520: ICICI Direct
    moneycontrol.com
  • CIPLA - Related Communities

    keyboard_arrow_down
    Share and discuss algorithms, strateg...
    Place for new investors to ask questi...
    Help fellow traders de-stress by shar...
    Share and discuss strategies for tax ...
    Want to know more about an upcoming I...
    MCX:MENTHAOIL
    MCX:CPO
    Purpose: Pool and discuss ideas & sug...
    Sector: Index
    Sector: Finance
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.